Contact
searchSearch
HMP Global
Login

Chronic Lymphocytic Leukemia Resource Center

Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024
Moritz Furstenau, MD
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology
From Oncology
Interview
Oncology Drug Shortages: Causes and Solutions
05/28/2024

 Ryan Motte, PharmD, CSP, Shields Health Solutions

 Ryan Motte, PharmD, CSP, Shields Hea...
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses...
05/28/2024
Journal of Clinical Pathways
News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
From Lymphoma, Leukemia & Myeloma Network
News
Measurable Residual Disease as a Treatment Guide for Patients with Chronic Lymphocytic Leukemia
01/30/2024
Emry Lloyd
In a recent study, Talha Munir, PhD, and colleagues investigated whether personalization of ibrutinib and venetoclax treatment according to measurable residual disease has an impact on patients’ progression-free survival.
In a recent study, Talha Munir, PhD, and colleagues investigated whether personalization of ibrutinib and venetoclax treatment according to measurable residual disease has an impact on patients’ progression-free survival.
In a recent study, Talha Munir,...
01/30/2024
Journal of Clinical Pathways
News
Zanubrutinib Shows Superior Long-Term Outcomes vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/04/2023
Emry Lloyd
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and...
12/04/2023
Journal of Clinical Pathways
News
Comparative Study of Nemtabrutinib and Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
12/04/2023
Emry Lloyd
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will...
12/04/2023
Journal of Clinical Pathways
Conference Coverage
Trends in the Use of Bruton Tyrosine Kinase Inhibitors and B-cell 2 Inhibitors for Treating CLL in Community Oncology Settings
11/29/2023
Grace Taylor, MS, MA
Jing-Zhou Hou, MD, and colleagues analyzed the implementation and influences of BTKis and BCL2is for treating patients with CLL among community oncologists since 2020.
Jing-Zhou Hou, MD, and colleagues analyzed the implementation and influences of BTKis and BCL2is for treating patients with CLL among community oncologists since 2020.
Jing-Zhou Hou, MD, and...
11/29/2023
Journal of Clinical Pathways
News
A Deeper Look Into Hypertension and Cardiovascular Toxicity Symptoms for Patients Treated With Ibrutinib
10/13/2023
Emry Lloyd
Max Gordon, MD, and colleagues evaluated the long-term effects in patients with chronic lymphocytic leukemia who reported hypertension or cardiovascular issues while receiving ibrutinib.
Max Gordon, MD, and colleagues evaluated the long-term effects in patients with chronic lymphocytic leukemia who reported hypertension or cardiovascular issues while receiving ibrutinib.
Max Gordon, MD, and colleagues...
10/13/2023
Journal of Clinical Pathways
News
Analysis of Outcomes for Patients With CLL Disease Progression While on Ibrutinib
09/14/2023
Emry Lloyd
In a recent analysis, researchers investigated the factors that contribute to worse outcomes for patients with CLL who experience disease progression while on ibrutinib.
In a recent analysis, researchers investigated the factors that contribute to worse outcomes for patients with CLL who experience disease progression while on ibrutinib.
In a recent analysis,...
09/14/2023
Journal of Clinical Pathways
Conference Coverage
Use of Pharmacogenomic Testing to Predict Bruton’s Tyrosine Kinase Inhibitor Treatment Intolerance
08/09/2023
Emry Lloyd
Researchers conducted a study to determine whether cytochrome P450 polymorphisms can contribute to treatment intolerance in patients receiving Bruton’s tyrosine kinase inhibitors.
Researchers conducted a study to determine whether cytochrome P450 polymorphisms can contribute to treatment intolerance in patients receiving Bruton’s tyrosine kinase inhibitors.
Researchers conducted a study to...
08/09/2023
Journal of Clinical Pathways

Expert Insights

Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024
Moritz Furstenau, MD
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology
Interview
Oncology Drug Shortages: Causes and Solutions
05/28/2024

 Ryan Motte, PharmD, CSP, Shields Health Solutions

 Ryan Motte, PharmD, CSP, Shields Hea...
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
Ryan Motte, PharmD, discusses...
05/28/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Adam Kittai, MD
Videos
A Real-World Analysis of Factors Leading to Racial Disparities in the Overall Survival of Patients with CLL
06/22/2023
Adam Kittai, MD
Adam Kittai, MD, The Ohio State University Comprehensive Cancer Center, discusses his study on the causes of racial disparities in the overall survival of patients with chronic lymphocytic leukemia.
Adam Kittai, MD, The Ohio State University Comprehensive Cancer Center, discusses his study on the causes of racial disparities in the overall survival of patients with chronic lymphocytic leukemia.
Adam Kittai, MD, The Ohio State...
06/22/2023
Journal of Clinical Pathways
Winston Wong
Editor Insights
A Look Back at Clinical Pathways in 2022
02/21/2023
Winston Wong, PharmD
This blog summarizes the Journal of Clinical Pathway's top 5 articles of 2022.
This blog summarizes the Journal of Clinical Pathway's top 5 articles of 2022.
This blog summarizes the Journal...
02/21/2023
Journal of Clinical Pathways
Justin Taylor, MD
Videos
Recent Advances in Chronic Lymphocytic Leukemia Treatment
12/06/2022
Justin Taylor, MD, answers a series of questions about recent advances in the treatment landscape for chronic lymphocytic leukemia.
Justin Taylor, MD, answers a series of questions about recent advances in the treatment landscape for chronic lymphocytic leukemia.
Justin Taylor, MD, answers a...
12/06/2022
Journal of Clinical Pathways
Kerry Rogers, MD
Videos
Progression-Free Survival Among Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
08/19/2022
Kerry Rogers, MD, discusses a retrospective cohort study looking at depth of response and progression-free survival outcomes among patients with chronic lymphocytic leukemia treated with ibrutinib.
Kerry Rogers, MD, discusses a retrospective cohort study looking at depth of response and progression-free survival outcomes among patients with chronic lymphocytic leukemia treated with ibrutinib.
Kerry Rogers, MD, discusses a...
08/19/2022
Journal of Clinical Pathways
Adam Kittai, MD
Videos
Examining Racial and Socioeconomic Disparities Among Patients With Chronic Lymphocytic Leukemia
06/14/2022
Adam Kittai, MD, discusses his study which examined Surveillance, Epidemiology, and End Results (SEER) program data to determine how race and socioeconomic status impact survival among patients with CLL.
Adam Kittai, MD, discusses his study which examined Surveillance, Epidemiology, and End Results (SEER) program data to determine how race and socioeconomic status impact survival among patients with CLL.
Adam Kittai, MD, discusses his...
06/14/2022
Journal of Clinical Pathways
Houda Hachad, PharmD
Interview
FDA Highlights Risks Associated With DPD Deficiency, Advises Testing Before Treatment
03/26/2025
Houda Hachad, PharmD
This interview explores the US Food and Drug Administration’s (FDA) updated guidance on dihydropyrimidine dehydrogenase (DPD) deficiency and its implications for improving patient safety through pre-treatment DPYD testing before...
This interview explores the US Food and Drug Administration’s (FDA) updated guidance on dihydropyrimidine dehydrogenase (DPD) deficiency and its implications for improving patient safety through pre-treatment DPYD testing before...
This interview explores the US...
03/26/2025
Journal of Clinical Pathways
Upal Basu Roy, PhD, MPH
Interview
Project PRIORITY: Elevating the Patient Voice in EGFR-Positive NSCLC Care
03/24/2025
Upal Basu Roy, PhD, MPH
In this interview, Upal Basu Roy, PhD, MPH, shares how by centering on patient experiences, Project PRIORITY reveals critical disparities in access to diagnostics, treatment, and palliative care for patients with epidermal growth factor...
In this interview, Upal Basu Roy, PhD, MPH, shares how by centering on patient experiences, Project PRIORITY reveals critical disparities in access to diagnostics, treatment, and palliative care for patients with epidermal growth factor...
In this interview, Upal Basu...
03/24/2025
Journal of Clinical Pathways
Videos
Why Pathways Matter: Editorial Advisory Board Testimonials
03/24/2025
F. Randy Vogenberg, PhD, FASHP
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal of Clinical Pathways has been at the forefront of advancing evidence-based, value-driven care through clinical pathways. As we celebrate our 10th anniversary, we’re highlighting the voices of key thought leaders...
For the past 10 years, Journal...
03/24/2025
Journal of Clinical Pathways
Kohli Headshot
Interview
Strengthening Patient Pathways With BIS for Lymphedema Surveillance
03/24/2025
Manpreet Kohli, MD
In this interview, Manpreet Kohli, MD, discusses the incorporation of bioimpedance spectroscopy into NAPBC standards, the impact of early lymphedema detection on survivorship, and how clinicians can better support patient-centered care...
In this interview, Manpreet Kohli, MD, discusses the incorporation of bioimpedance spectroscopy into NAPBC standards, the impact of early lymphedema detection on survivorship, and how clinicians can better support patient-centered care...
In this interview, Manpreet...
03/24/2025
Journal of Clinical Pathways
Chelsea Renfro, PharmD
Interview
How Integrated Health System Pharmacies Enhance Treatment Adherence and Adverse Effect Management for CLL
03/21/2025
Houston Wyatt, PharmD; Chelsea E. Renfro, PharmD; Stephanie White, PharmD
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how integrated health system pharmacy services can improve medication adherence, persistence, and adverse effect management in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
This interview explores how...
03/21/2025
Journal of Clinical Pathways
Videos
Progress and Unmet Needs in Post-IO Treatment for Metastatic RCC
03/19/2025
Neil Shah, MD
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah discusses the challenges of treatment sequencing for metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitor therapy, highlighting findings from his study on post-IO treatment efficacy and the...
In this interview, Dr Neil Shah...
03/19/2025
Journal of Clinical Pathways
Graf Headshot
Interview
The Future of Chronic Lymphocytic Leukemia Management with Targeted Therapies
03/17/2025
In this interview, an expert discusses the preclinical development and clinical impact of zanubrutinib in chronic lymphocytic leukemia, highlighting key findings from pivotal trials, comparisons with other therapies, and future research...
In this interview, an expert discusses the preclinical development and clinical impact of zanubrutinib in chronic lymphocytic leukemia, highlighting key findings from pivotal trials, comparisons with other therapies, and future research...
In this interview, an expert...
03/17/2025
Journal of Clinical Pathways
Oncology Innovations
Videos
Advancing Value-Based Oncology With the Predictable Cost of Care Working Group: Part 2
03/17/2025
Gordon Kuntz; Carole Tremonti, RN, MBA
In this episode of Oncology Innovations, experts discuss the Predictable Cost of Care Working Group’s efforts to develop a standardized model for assessing oncology treatment costs, highlighting insights from phase I, the goals of phase II,...
In this episode of Oncology Innovations, experts discuss the Predictable Cost of Care Working Group’s efforts to develop a standardized model for assessing oncology treatment costs, highlighting insights from phase I, the goals of phase II,...
In this episode of Oncology...
03/17/2025
Journal of Clinical Pathways
Brian S.
Interview
Key Advancements in Immunotherapy for Endometrial Cancer
03/13/2025
Brian M. Slomovitz, MD, MS
A guest expert discusses groundbreaking research on pembrolizumab in adjuvant treatment for endometrial cancer, highlighting the significant impact on reducing recurrence risk in patients with deficient mismatch repair and the need for...
A guest expert discusses groundbreaking research on pembrolizumab in adjuvant treatment for endometrial cancer, highlighting the significant impact on reducing recurrence risk in patients with deficient mismatch repair and the need for...
A guest expert discusses...
03/13/2025
Journal of Clinical Pathways
Brufsky Headshot
Interview
Transforming Metastatic Breast Cancer Care With AI and Real-World Evidence
03/11/2025
Adam Brufsky, MD, PhD
In this interview, Adam Brufsky, MD, PhD, discusses the evolving treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer, the impact of CDK4/6 inhibitors, the role of genomic assays and artificial intelligence...
In this interview, Adam Brufsky, MD, PhD, discusses the evolving treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer, the impact of CDK4/6 inhibitors, the role of genomic assays and artificial intelligence...
In this interview, Adam Brufsky,...
03/11/2025
Journal of Clinical Pathways

Newsfeed

News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
News
Measurable Residual Disease as a Treatment Guide for Patients with Chronic Lymphocytic Leukemia
01/30/2024
Emry Lloyd
In a recent study, Talha Munir, PhD, and colleagues investigated whether personalization of ibrutinib and venetoclax treatment according to measurable residual disease has an impact on patients’ progression-free survival.
In a recent study, Talha Munir, PhD, and colleagues investigated whether personalization of ibrutinib and venetoclax treatment according to measurable residual disease has an impact on patients’ progression-free survival.
In a recent study, Talha Munir,...
01/30/2024
Journal of Clinical Pathways
News
Zanubrutinib Shows Superior Long-Term Outcomes vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/04/2023
Emry Lloyd
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and...
12/04/2023
Journal of Clinical Pathways
News
Comparative Study of Nemtabrutinib and Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
12/04/2023
Emry Lloyd
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will...
12/04/2023
Journal of Clinical Pathways
News
A Deeper Look Into Hypertension and Cardiovascular Toxicity Symptoms for Patients Treated With Ibrutinib
10/13/2023
Emry Lloyd
Max Gordon, MD, and colleagues evaluated the long-term effects in patients with chronic lymphocytic leukemia who reported hypertension or cardiovascular issues while receiving ibrutinib.
Max Gordon, MD, and colleagues evaluated the long-term effects in patients with chronic lymphocytic leukemia who reported hypertension or cardiovascular issues while receiving ibrutinib.
Max Gordon, MD, and colleagues...
10/13/2023
Journal of Clinical Pathways
News
Analysis of Outcomes for Patients With CLL Disease Progression While on Ibrutinib
09/14/2023
Emry Lloyd
In a recent analysis, researchers investigated the factors that contribute to worse outcomes for patients with CLL who experience disease progression while on ibrutinib.
In a recent analysis, researchers investigated the factors that contribute to worse outcomes for patients with CLL who experience disease progression while on ibrutinib.
In a recent analysis,...
09/14/2023
Journal of Clinical Pathways
News
Study Analyzes Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020
05/11/2023
Grace Taylor, MS, MA
Edward R. Scheffer Cliff, MBBS, MPH, Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, and colleagues recently evaluated...
Edward R. Scheffer Cliff, MBBS, MPH, Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, and colleagues recently evaluated...
Edward R. Scheffer Cliff, MBBS,...
05/11/2023
Journal of Clinical Pathways
News
FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
04/24/2023
Gina Tomaine
On January 19, 2023, the Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval was based on the SEQUOIA and ALPINE trials, respectively. The...
On January 19, 2023, the Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval was based on the SEQUOIA and ALPINE trials, respectively. The...
On January 19, 2023, the Food...
04/24/2023
Journal of Clinical Pathways
News
The Ongoing Impact of COVID-19 on Caregivers of Patients With Chronic Lymphocytic Leukemia
03/15/2023
Grace Taylor, MS, MA
A recent study investigated the impact of COVID-19 on caregivers of patients with CLL during the post-vaccine phase of the pandemic and aimed to identify what resources are needed to better support these caregivers.
A recent study investigated the impact of COVID-19 on caregivers of patients with CLL during the post-vaccine phase of the pandemic and aimed to identify what resources are needed to better support these caregivers.
A recent study investigated the...
03/15/2023
Journal of Clinical Pathways
News
Elevated Risk of Atrial Fibrillation or Stroke in Patients With CLL Receiving Ibrutinib Treatment Has Minimal Impact on TTNT and TTD
02/23/2023
Grace Taylor, MS, MA
A recent study evaluated the real-world persistence and time to next treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), including those at high risk for atrial fibrillation or stroke, who receive...
A recent study evaluated the real-world persistence and time to next treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), including those at high risk for atrial fibrillation or stroke, who receive...
A recent study evaluated the...
02/23/2023
Journal of Clinical Pathways
News
Academic Cancer Centers Improve Outcomes for Patients With Mantle Cell Lymphoma
03/18/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell...
03/18/2025
Journal of Clinical Pathways
News
Improving Health Care Access for Immigrants With Disabilities in North America
03/14/2025
Hannah Musick
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...
Exploring the barriers and...
03/14/2025
Journal of Clinical Pathways
News
AI Revolutionizes Early Detection and Diagnosis of Gastric Cancer
03/14/2025
Lisa Kuhns, PhD, MD
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...
Artificial intelligence (AI) is...
03/14/2025
Journal of Clinical Pathways
News
Oral JAK2 Inhibitor Offers a Viable Second-Line Treatment for Myelofibrosis, but Challenges Remain
03/13/2025
Lisa Kuhns, PhD, MD
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.
Fedratinib, an oral JAK2...
03/13/2025
Journal of Clinical Pathways
News
Early Measurable Residual Disease Assessment Predicts Survival in Patients With Mantle Cell Lymphoma
03/12/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell...
03/12/2025
Journal of Clinical Pathways
News
Radiomics and AI Advance NSCLC Staging Precision
03/10/2025
Juliet Gallagher
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in...
03/10/2025
Journal of Clinical Pathways
News
Evaluating the Cost Benefits and Clinical Potential of Serum Pepsinogen Screening for Gastric Cancer
03/07/2025
Juliet Gallagher
A recent study published in Gastro Hep Advances evaluated the cost-effectiveness of using serum pepsinogen (PG) screening for the early detection of gastric cancer (GC) in the US.
A recent study published in Gastro Hep Advances evaluated the cost-effectiveness of using serum pepsinogen (PG) screening for the early detection of gastric cancer (GC) in the US.
A recent study published in...
03/07/2025
Journal of Clinical Pathways
News
Strategies to Enhance Cancer Screening Access for Patients With Disabilities
03/06/2025
Juliet Gallagher
Patients with disabilities face significant barriers to cancer screening, including communication challenges, physical inaccessibility, financial constraints, and provider assumptions, highlighting the need for targeted interventions to...
Patients with disabilities face significant barriers to cancer screening, including communication challenges, physical inaccessibility, financial constraints, and provider assumptions, highlighting the need for targeted interventions to...
Patients with disabilities face...
03/06/2025
Journal of Clinical Pathways
News
Machine Learning Identifies Key Genomic Markers to Predict CPI Outcomes in NSCLC
03/06/2025
Grace Taylor, MS, MA
A machine learning-driven study analyzing genomic data from patients with non-small cell lung cancer (NSCLC) reveals specific mutations and pathways that influence resistance to checkpoint inhibitor immunotherapy, offering potential targets...
A machine learning-driven study analyzing genomic data from patients with non-small cell lung cancer (NSCLC) reveals specific mutations and pathways that influence resistance to checkpoint inhibitor immunotherapy, offering potential targets...
A machine learning-driven study...
03/06/2025
Journal of Clinical Pathways
News
Ruxolitinib Prior to Transplantation Linked to Better Survival in Myelofibrosis
03/05/2025
Grace Taylor, MS, MA
Pre-transplant use of ruxolitinib may enhance survival outcomes for patients with myelofibrosis undergoing stem cell transplantation.
Pre-transplant use of ruxolitinib may enhance survival outcomes for patients with myelofibrosis undergoing stem cell transplantation.
Pre-transplant use of...
03/05/2025
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: First-Line Venetoclax Plus Obinutuzumab Among Patients With CLL or SLL
04/18/2022
True or False: Patients with CLL or SLL who discontinued venetoclax as first-line therapy had a greater disease burden and risk of tumor lysis syndrome when compared with patients who completed at least 12 cycles of treatment with venetoclax.
True or False: Patients with CLL or SLL who discontinued venetoclax as first-line therapy had a greater disease burden and risk of tumor lysis syndrome when compared with patients who completed at least 12 cycles of treatment with venetoclax.
True or False: Patients with CLL...
04/18/2022
Journal of Clinical Pathways
Quiz
Quiz: The Impact of Atrial Fibrillation on CLL
03/24/2022
True or False: Patients with CLL with atrial fibrillation may be at a significantly decreased risk of all-cause mortality, cardiac-related mortality, and stroke.
True or False: Patients with CLL with atrial fibrillation may be at a significantly decreased risk of all-cause mortality, cardiac-related mortality, and stroke.
True or False: Patients with CLL...
03/24/2022
Journal of Clinical Pathways
Quiz
Quiz: Risk of Infusion Reactions in Patients With CLL Receiving Obinutuzumab
02/22/2022
True or False: Using chlorambucil before obinutuzumab and using a slow initial obinutuzumab infusion rate may reduce risk of infusion reactions in patients with CLL.
True or False: Using chlorambucil before obinutuzumab and using a slow initial obinutuzumab infusion rate may reduce risk of infusion reactions in patients with CLL.
True or False: Using...
02/22/2022
Journal of Clinical Pathways
Quiz
Quiz: Ibrutinib Safety for Relapsed/Refractory CLL
01/13/2022
True or False: Single-agent ibrutinib is safe and effective for relapsed/refractory CLL in routine practice.
True or False: Single-agent ibrutinib is safe and effective for relapsed/refractory CLL in routine practice.
True or False: Single-agent...
01/13/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Venetoclax Plus Obinutuzumab for CLL
11/22/2021
True or False: Fixed duration venetoclax plus obinutuzumab for 12 months is a cost-effective first-line treatment option for unfit patients with chronic lymphocytic leukemia.
True or False: Fixed duration venetoclax plus obinutuzumab for 12 months is a cost-effective first-line treatment option for unfit patients with chronic lymphocytic leukemia.
True or False: Fixed duration...
11/22/2021
Journal of Clinical Pathways
Quiz
Quiz: Treatment Discontinuation Among Patients With CLL
10/19/2021
True or False: The most common reason for novel oral drug discontinuation among patients with CLL in the real-world setting is due to adverse events.
True or False: The most common reason for novel oral drug discontinuation among patients with CLL in the real-world setting is due to adverse events.
True or False: The most common...
10/19/2021
Journal of Clinical Pathways
Quiz
Quiz: Cardiovascular Risks for Patients With CLL Receiving Ibrutinib
10/08/2021
True or False: Ibrutinib is associated with higher risk of atrial fibrillation, bleeding, and heart failure, but not acute myocardial infarction or stroke among patients with chronic lymphocytic leukemia.
True or False: Ibrutinib is associated with higher risk of atrial fibrillation, bleeding, and heart failure, but not acute myocardial infarction or stroke among patients with chronic lymphocytic leukemia.
True or False: Ibrutinib is...
10/08/2021
Journal of Clinical Pathways
Quiz
Quiz: Bendamustine Costs for Patients With CLL and NHL
09/10/2021
True or False: Small-volume, short-duration infusions of bendamustine for patients with CLL and NHL are associated with low acquisition costs and low administration labor costs compared to large-volume, long-duration infusions.
True or False: Small-volume, short-duration infusions of bendamustine for patients with CLL and NHL are associated with low acquisition costs and low administration labor costs compared to large-volume, long-duration infusions.
True or False: Small-volume,...
09/10/2021
Journal of Clinical Pathways
Quiz
Quiz: Rituximab Cost for CLL and NHL
07/23/2021
True or False: Intravenous rituximab-abbs yields significant annual cost savings compared to subcutaneous rituximab for patients with NHL and CLL.
True or False: Intravenous rituximab-abbs yields significant annual cost savings compared to subcutaneous rituximab for patients with NHL and CLL.
True or False: Intravenous...
07/23/2021
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use